Diabetes Mellitus, Type 2 Clinical Trial
— mDASOfficial title:
mHealth for Diabetes Adherence Support
| Verified date | June 2023 |
| Source | University of Illinois at Chicago |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this research study is to determine the benefit and cost of including health coaches, clinical pharmacists and mobile health (mHealth) tools such as text messaging and videoconferencing in diabetes management support services for African-Americans and Latinos with uncontrolled Type 2 Diabetes.
| Status | Completed |
| Enrollment | 221 |
| Est. completion date | January 7, 2022 |
| Est. primary completion date | January 7, 2022 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 21 Years to 75 Years |
| Eligibility | Inclusion Criteria: - Self-identified as Latino/Hispanic or African-American - Verbal fluency in English or Spanish - Latest A1c = 8.0% (within 3 mo) - History of Type 2 Diabetes (> 1 year) - Between the ages of 21 and 75 years - Unlimited mobile phone/text messaging plan with ability to reply to text messages - Home environment capable of video conferencing with wireless signal - Receives primary care at UI Health clinical site for at least one year, with one visit during past year - Able and willing to provide informed consent (agree to data collection requirements, accept randomization, agree to home visitation with HC and pharmacist involvement, and participate for two years) Exclusion Criteria: - Unable to verbalize comprehension of study or impaired decision making - Family/household member already participating in same study - Currently receiving regular pharmacist support through Medication Therapy Management or equivalent - History of, or planned, gastric bypass or transplant surgery - History of bipolar or psychotic disorder - Other severe comorbidities that require complex, aggressive, or palliative treatment, e.g., stage 4 or greater renal disease, liver failure, cancer (other than nonmelanoma skin cancer), terminal illness - Investigator discretion for safety concerns |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of Illinois Hospital and Health Sciences System | Chicago | Illinois |
| Lead Sponsor | Collaborator |
|---|---|
| University of Illinois at Chicago | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Sharp LK, Biggers A, Perez R, Henkins J, Tilton J, Gerber BS. A Pharmacist and Health Coach-Delivered Mobile Health Intervention for Type 2 Diabetes: Protocol for a Randomized Controlled Crossover Study. JMIR Res Protoc. 2021 Mar 10;10(3):e17170. doi: 10. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Healthcare utilization | This will include costs associated with hospital admissions, emergency room and outpatient visits and prescription medications. | 24 months | |
| Other | Program cost | This will include costs associated with the intervention including pharmacists and health coaches (training, salaries, implementation), educational materials, tablet computers and associated data service, text messaging and videoconferencing. | 24 months | |
| Other | Health Coach Satisfaction | A survey administered to the patient for feedback on their assigned health coach. | 1 year after health coach assignment | |
| Primary | Hemoglobin A1c | 24 months | ||
| Secondary | Self-reported medication adherence | A 3-item questionnaire will be administered to measure adherence to diabetes medications. | 24 months | |
| Secondary | Blood Pressure | 24 months | ||
| Secondary | LDL Cholesterol | LDL Cholesterol will be measured as part of a Full Lipid profile blood test. | 24 months | |
| Secondary | Diabetes Self-Management | Self-management will be measured by the revised 11-item Summary of Diabetes Self Care Activities questionnaire. | 24 months | |
| Secondary | Health related quality of life | General health-related quality of life will be measured by the EuroQOL 5D (EQ-5D). | 24 months | |
| Secondary | Diabetes related quality of life | Diabetes-related quality of life will be measured by the Diabetes Distress Screening Instrument (DDS4). | 24 months | |
| Secondary | Depression | Measured with the nine-item Patient Health Questionnaire (PHQ-9) | 24 months | |
| Secondary | Alcohol Misuse | Measured using the 3-item AUDIT-C questionnaire | 24 months | |
| Secondary | BMI | Height and weight will be taken at each time point to determine BMI | 24 months | |
| Secondary | Social Support | 4-item questionnaire measuring satisfaction with support from friends, family and health care team | 24 months | |
| Secondary | Diabetes Self-efficacy | 8 -item questionnaire measuring confidence in diabetes self-management skills | 24 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
| Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
| Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
| Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
| Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
| Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
| Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
| Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
| Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
| Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
| Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
| Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
| Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |